Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMBINE 1
2020-005281-34Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Dec 2021
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3 trial of icosema, insulin icodec and semaglutide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Change in glycated haemoglobin (HbA1c). Started Dec 2021; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2020-005281-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005281-34.